

החברה הישראלית  
לחקר הכבד  
Israel Association for the  
Study of the Liver




# ANNUAL MEETING

8-10/6/2017 **DAN EILAT HOTEL**

## Hot Topics in Hepatology

Scientific Program



## THURSDAY JUNE 8TH, 2017

11:00-13:00

**Liver Forum**

“Blue” Hall | Moderator: Dr. Yoav Lurie

Sponsored by  | 

11:00-11:30

**In the Footsteps of the Liver**

Dr. Tamar Berger, Beilinson Hospital

11:30-12:00

**DECOPPERING - מחלת וילסון: נחושים ל**

Dr. Ella Wiezmann, Rambam Medical Center

12:00-12:30

**Tacrolimus Vs Cyclosporine after liver transplantation**

Dr. Oranit Cohen- Ezra, Tel Hashomer

12:30-13:00

**Treating Hepatitis C beyond AASLD/EASL recommendations**

Dr. Yaakov Maor, Kaplan Medical

13:00-13:30

**Light Lunch**

13:30-13:45

**Opening**

“Blue” Hall

13:30-13:35


**Greetings**

Prof. Eli Zuckerman, IsASL Chairman

13:35-13:45

**Hepatology 2017- לאן?**

Prof. Ran Tur-Kaspa, Director, Liver Institute, Beilinson Hospital



13:45-15:55

**SESSION 1: Toxic Liver Disease, fibrosis & Cholestasis  
“Blue” Hall**

**Chairs: Prof. Rafi Bruck, Dr. Rawi Hazan**

13:45-10:53

**Novel anti-LOXL2 inhibitor paves the way for macrophage-mediated collagen degradation in experimental liver fibrosis**

Mordehay Kelpfish<sup>2</sup>, Milena Vugman<sup>1</sup>, Eli Brazowski<sup>1</sup>,

**Chen Varol<sup>1</sup>**, Irit Sagi<sup>2</sup>

<sup>1</sup> The Research Center for Digestive Tract and Liver Diseases and Department of Clinical Microbiology and Immunology, Tel-Aviv Sourasky Medical Center and Tel-Aviv University, Israel

<sup>2</sup> Department of Biological Regulation, Weizmann Institute of Science, Israel

13:53-14:01

**The PARP-1 inhibitor 3-aminobenzamide prevents Concanavalin A-induced acute hepatitis in mice by a joint anti-inflammatory and anti-oxidative mechanism**

**Joram Wardi<sup>1</sup>**, Orna Ernst<sup>4</sup>, Anna Lilja<sup>4</sup>, Hussein Aeed<sup>1</sup>, Sebastian Katz<sup>4</sup>, Dolev Katz<sup>4</sup>, Olga Bernadsky<sup>2</sup>, Rajendar Kandhikonda<sup>5</sup>, Yona Avni<sup>1</sup>, Roy Weinstein<sup>5</sup>, Alexander Biro<sup>3</sup>, Tsaffir Zor<sup>4</sup>

<sup>1</sup> Gastroenterology, Wolfson Medical Center, Israel, <sup>2</sup> Pathology, Wolfson Medical Center, Israel, <sup>3</sup> Nephrology, Wolfson Medical Center, Israel, <sup>4</sup> Biochemistry and Life Sciences, Life Sciences, Tel-Aviv University, Israel, <sup>5</sup> Molecular biology & ecology of plants, Tel-Aviv University, Life Sciences, Israel

14:01-14:09

**Thiopurine metabolites measurement in adult patients with autoimmune hepatitis**

**Hisham Sholy**, Ella Veitsman, Tarek Saadi

Liver unit, Rambam Health Care Campus, Israel



14:09-14:17

**Namodenoson (CF102) Prevents Progression of Liver Fibrosis**

Johnny Amer<sup>1</sup>, **Rifaat Safadi**<sup>1</sup>, Ahmad Salhab<sup>1</sup>, Shira Cohen<sup>2</sup>,  
Prina Fishman<sup>2</sup>

<sup>1</sup> Liver & Gastroenterology Units, Hadassah-Hebrew University  
Hospital, Israel, <sup>2</sup> Can-Fite BioPharma Ltd., Can-Fite BioPharma  
Ltd., Israel

14:17-14:25

**Metabolic and cardiovascular co-morbidities are associated  
with severe complications following Transjugular Intrahepatic  
Portosystemic Shunt :a 10 year single center experience**

**Neta Gottlieb**<sup>1</sup>, Jonathan Brill<sup>2</sup>, Shiri Sherf Dagan<sup>1</sup>, Isaac Kori<sup>3</sup>,  
Oren Shibolet<sup>1</sup>

<sup>1</sup> Department of gastroenterology and liver diseases, Tel-Aviv  
medical center and the Sackler faculty of medicine, Tel-Aviv,  
Israel, <sup>2</sup> Sackler faculty of medicine, Tel-Aviv university, Tel-Aviv,  
Israel, <sup>3</sup> Interventional radiology, Tel-Aviv medical center and  
the Sackler faculty of medicine, Tel-Aviv, Israel

14:25-14:33

**Effect of the autonomic nervous system on splanchnic  
circulation before and after meals**


**Farid Zreik**, Reshef Meshulam, Oren Shibolet, Jacob Giris  
Medicine F, J. Recanati Autonomic Dysfunction Center, Tel Aviv  
Sourasky Medical Center & Faculty of Medicine, Israel

14:33-14:41

**Amiodarone induced adipose tissue endoplasmic  
reticulum stress and lipolysis may contribute to hepatic lipid  
accumulation**

**Einav Hubel-Manor**, Inbal Hour, Roy Avraham, Isabel Zvibel,  
Oren Shibolet

Gastroenterology Institute, Sackler Faculty of Medicine, Tel-Aviv  
University, Israel



14:45-15:25

### **PBC-Panoramic View of New and emerging treatments**

**Prof. Gideon Hirschfield**

Professor of Autoimmune Liver Disease at the University of Birmingham, and Honorary Consultant Transplant Hepatologist at Queen Elizabeth Hospital, University Hospitals Birmingham, UK

Sponsored by  **NEOPHARM ISRAEL**  
NEOPHARM GROUP

15:25-15:50

### **Coffee Break, Visit to the Poster Exhibit & Exhibit Hall**

15:50-18:00

### **SESSION 2: Fibrosis, Cholestasis & Viral Hepatitis "Blue" Hall**

**Chairs: Dr. Amir Shlomai, Dr. Tarek Saadi**

15:50-16:00

### **The Dual CCR2/CCR5 Inhibitor Cenicriviroc Ameliorates Murine Primary Biliary Cholangitis**

**Debby Reuveni**<sup>1</sup>, Debby Reuveni<sup>1</sup>, Ayelet Kaminitz<sup>1</sup>, Siwar Assi<sup>1</sup>, Patrick Leung<sup>3</sup>, Pamela Vig<sup>4</sup>, Eli Brazowski<sup>2</sup>, Oren Shibolet<sup>1</sup>, Eric Gershwin<sup>3</sup>, Ehud Zigmond<sup>1</sup>

<sup>1</sup> The Research Center for Digestive Diseases, Gastroenterology and Liver disease institute, Tel Aviv-Sourasky Medical Center, Israel, <sup>2</sup> Department of Pathology, Sourasky Medical Center, Israel, <sup>3</sup> Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, USA


<sup>4</sup> Allergen, Allergen plc, USA

16:00-16:20

### **Hot Topic 1-PSC –Clinical challenges in practice**

**Prof. Gideon Hirschfield**

Professor of Autoimmune Liver Disease at the University of Birmingham, and Honorary Consultant Transplant Hepatologist at Queen Elizabeth Hospital, University Hospitals Birmingham, UK



16:20-16:28

**Point Shear Wave Elastography Method for Assessing Liver Stiffness in Different Etiologies of Liver Diseases – A Prospective study**

**Tarek Saadi**<sup>1</sup>, Johad Khoury<sup>1</sup>, Widad Toukan<sup>1</sup>,  
Hisham Sholy<sup>1</sup>, Rimma Krimasky<sup>1</sup>, Vered Ben Hakoon<sup>1</sup>,  
Ella Veitzman<sup>1</sup>, Yaakov Baruch<sup>1</sup>, Diana Gaitini<sup>2</sup>

<sup>1</sup> Liver Unit, Rambam: Human Health Care Campus, Haifa, Israel

<sup>2</sup> Radiology department, Rambam: Human Health Care Campus, Haifa, Israel

16:30 -17:15

**HCV: lesson learned from clinical studies to real world data**

**Prof. Steven Flamm**

Division of Hepatology ,Northwestern University Feinberg School of Medicine ,Chicago, Illinois, USA

Sponsored by  **MSD**  
INVENTING FOR LIFE

17:15-17:23

**Vitamin D antagonizes the expression of genes that are epigenetically regulated by Hepatitis C virus**

Romy Zemel<sup>1</sup>, Noa Rapaport<sup>1</sup>, Shira Perez<sup>2,3</sup>,  
Eteedal Morad<sup>3</sup>, Marcela Karpuz<sup>4</sup>, Amiram Ravid<sup>5</sup>, Meital Gal-Tanamy<sup>2</sup>, Izhak Haviv<sup>3</sup>, **Ran Tur-Kaspa**<sup>6,7</sup>

<sup>1</sup> Molecular Hepatology Lab., Tel-Aviv University , FMRC, Israel

<sup>2</sup> Molecular Virology Lab., Bar-Ilan University, Faculty of Medicine in the Galilee, Israel


<sup>3</sup> Cancer Personalized Medicine and Diagnostic Genomics Lab, Bar-Ilan University, Faculty of Medicine in the Galilee, Israel

<sup>4</sup> Genomic Center, Bar-Ilan University, Faculty of Medicine in the Galilee, Israel

<sup>5</sup> Molecular Endocrinology, Tel-Aviv University, FMRC, Israel

<sup>6</sup> Liver Institute, Rabin Medical Center, Beilinson Hospital, Israel

<sup>7</sup> Faculty of Medicine in the Galilee, Bar-Ilan University, Israel



17:25-17:55 **Novel treatment options for Hepatitis B and D Virus infection:  
Entry Inhibition as a potent concept to prevent intraheptic  
spread of HBV cccDNA and HDV RNA**

**Prof. Stephan Urban**

Head, Translational Virology unit , Department of Infectious  
Diseases, Molecular Virology Heidelberg University Hospital,  
Germany

17:55-18:10 **Coffee Break, Visit at the Poster Exhibit & Exhibit Hall**

18:10-19:30 **SESSION 3: Viral Hepatitis  
“Blue” Hall**

**Chairs: Dr. Tania Berdichevski, Dr. Marius Braun**

18:10-18:18 **Increased killer B cells: Are they associated with increased viral  
load and autoimmunity in patients with chronic HCV infection?**

**Eli Zuckerman**<sup>1</sup>, Nasren Eiza<sup>2</sup>, Mattias Karlebach<sup>3</sup>,  
Tova Rainess<sup>3</sup>, Yair Goldberg<sup>2</sup>, Elias Toubi<sup>2</sup>,  
Zahava Vadasz<sup>2</sup>

<sup>1</sup> Liver Unit, Carmel Medical Center, Technion Faculty of  
Medicine, Israel

<sup>2</sup> Division of Allergy & Clinical Immunology, Bnai Zion Medical  
Center, Israel


<sup>3</sup> Institute of Gastroenterology, Bnai Zion Medical Center, Israel

18:20-19:05 **It's all about the Pan- moving forward with HCV treatment**

**Dr. Ashley Brown**

Consultant Hepatologist, Imperial College Healthcare NHS Trust  
St. Mary's Hospital, UK

Sponsored by **abbvie**



19:05-19:13

**Prospective assessment of the impact of successful DAAs treatment on liver fibrosis stage and predictors of fibrosis regression in patients with chronic hepatitis C**

**Yana Davidov-Derevyanko**<sup>1</sup>, Yeruham Kleinbaum<sup>1,3</sup>,  
Yael Inbar<sup>1,3</sup>, Oranit Cohen-Ezra<sup>1,4</sup>, Ella Veitsman<sup>2</sup>, Tanya  
Berdichevsky<sup>1</sup>, Perez Weiss<sup>1</sup>, Maria Lihter<sup>1</sup>, Sima Katerginsky<sup>1,3</sup>,  
Avishag Hassid<sup>1</sup>, Keren Tzaraf<sup>1</sup>, Ziv Ben-Ari<sup>1,4</sup>

<sup>1</sup> Liver Disease Center, Sheba Medical Center, Israel

<sup>2</sup> Liver Disease Center, Rambam Medical Center, Israel

<sup>3</sup> Department of Radiology, Sheba Medical Center, Israel

<sup>4</sup> Sackler School of Medicine, Tel Aviv University, Israel



**FRIDAY JUNE 9TH, 2017**

**PARALLEL SESSION - NURSES**  
**מושב אחיות ומתאמות מחקר**

07:30-09:30

אולם קורל • Coral Hall

Sponsored by



המושב בחסות

**Extrahepatic HCV manifestations**

07:30-08:30

פרופ' אלי צוקרמן

**ליזוי מטופל co-infection ושיתוף הפעולה עם יחידת HIV**

08:30-08:45

רימה קרמסקי, א. אחראית יחידת כבד מרכז רפואי רמב"ם

**מקום האחות בהדרכה בטיפול בחולי כבד שומני ובשילוב עם HCV**

08:45-09:00

יעל חריף, א. אחראית יחידת כבד מרכז רפואי בלינסון

**ביופסיית כבד - כאב חווית המטופל ומה שביניהם**

09:00-09:15

קן צארף, א. אחראית יחידת כבד מרכז רפואי שיבא

**איתור חולי הפטיטיס C במחוז חיפה וגליל מערבי**

09:15-09:30

אורלי אזולאי, א. אחראית יחידת כבד מרכז רפואי כרמל

08:00-09:30


**SESSION 4: Non Alcoholic Fatty Liver disease, Viral Hepatitis**  
**"Blue" Hall**

Chairs: Prof. Rifaat Safadi, Dr. Michal Carmiel-Hagai

08:00-08:08

**NK cell apoptosis correlates with fibrosis progression in Nonalcoholic-Fatty Liver-Disease via insulin receptor and mTOR pathway**

**Johnny Amer**, Ahmad Salhab, Sarit Doron, Rifaat Safadi  
Liver & Gastroenterology Units, Hadassah-Hebrew University Hospital, Israel



08:08-08:16

**Circulating Levels of the Chemokine CCL24 and its Receptor in Patients with Non-alcoholic Fatty Liver Disease**

**Yaakov Maor**<sup>1</sup>, Dan Haberman<sup>2</sup>, Michal Segal-Salto<sup>3</sup>, Avi Katav<sup>3</sup>, Sharon Hashmueli<sup>3</sup>, Jacob George<sup>2</sup>, Adi Mor<sup>3</sup>

<sup>1</sup> Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Israel, <sup>2</sup> Heart Center, Kaplan Medical Center, Rehovot, Affiliated to the Hebrew university, Jerusalem, Israel

<sup>3</sup> NA, ChemomAb Ltd, Israel

08:16-08:24

**CM-101, a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model**

**Ziv Ben-Ari**<sup>1</sup>, Michal Segal-Salto<sup>2</sup>, Avi Katav<sup>2</sup>, Sharon Hashmueli<sup>2</sup>, Jacob George<sup>3</sup>, Dan Haberman<sup>3</sup>, Yaacov Maor<sup>4</sup>, Adi Mor<sup>2</sup>

<sup>1</sup> Liver Diseases Center, Sheba Medical Center, Israel,

<sup>2</sup> Chemomab, ChemomAb Ltd, Israel, <sup>3</sup> Heart Institute, Kaplan Medical Center, Israel, <sup>4</sup> Liver Diseases service, Kaplan Medical Center, Israel

08:24-08:32

**Non-alcoholic Fatty Liver Disease in Non-obese Young Adults**

**Yaakov Maor**<sup>1</sup>, Salah Daher<sup>2,3</sup>, Eran Israeli<sup>3</sup>, Stephen DH Malnick<sup>4</sup>, Ehud Melzer<sup>1</sup>, Lior Katz<sup>5</sup>

<sup>1</sup> Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Israel, <sup>2</sup> NA, the Israeli Defense Force, Israel

<sup>3</sup> Department of Gastroenterology and Hepatology, Hadassah Medical Center, Israel, <sup>4</sup> Department of Internal Medicine C, Kaplan Medical Center, Israel, <sup>5</sup> Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel


08:32-08:40

**The association of dietary meat type and its cooking method with non-alcoholic fatty liver disease and insulin resistance**

Dana Ivancovsky<sup>1</sup>, Revital Kariv<sup>2,3</sup>, Naomi Fliss-Isakov<sup>2,3</sup>, Muriel Webb<sup>2,3</sup>, Oren Shibolet<sup>2,3</sup>, **Shira Zelber-Sagi**<sup>1,2</sup>

<sup>1</sup> University of Haifa, School of Public Health, Israel

<sup>2</sup> Tel Aviv Medical Center, Department of Gastroenterology, Israel, <sup>3</sup> Tel Aviv University, Faculty of Medicine, Israel



08:40-08:48

**The impact of bariatric surgery on nonalcoholic fatty liver disease and cardiovascular risk utilizing non-invasive measures**

**Carmit Netanel**<sup>1</sup>, David Goitein<sup>2</sup>, Moshe Rubin<sup>2,3</sup>, Michael Shechter<sup>3,4</sup>, Yeruham Kleinbaum<sup>5</sup>, Sima Katsherginsky<sup>5</sup>, Hila Hermon<sup>2</sup>, Rina Hemi<sup>6</sup>, Keren Tsaraf<sup>1</sup>, Ardita Donuzi<sup>1</sup>, Michal Safran<sup>1</sup>, Irina Tachlytski<sup>1</sup>, Amir Herman<sup>3,7</sup>, Pablo Ortiz<sup>8</sup>, Ziv Ben-Ari<sup>1,3</sup>

<sup>1</sup> Liver Disease Center, Sheba Medical Center, Tel Hashomer, Israel, <sup>2</sup> Bariatric and Metabolic Surgery, Sheba Medical Center, Tel Hashomer, Israel, <sup>3</sup> Sackler School of Medicine, Tel Aviv University, Israel, <sup>4</sup> Leviev Heart center, Sheba Medical Center, Tel Hashomer, Israel, <sup>5</sup> Department of Radiology, Sheba Medical Center, Tel Hashomer, Israel, <sup>6</sup> Institute of Endocrinology, Sheba Medical Center, Tel Hashomer, Israel, <sup>7</sup> Department of Orthopedics, Sheba Medical Center, Tel Hashomer, Israel  
<sup>8</sup> OWL, Parque Tecnológico de Bizkaia, Spain

08:48-08:56

**Predictors of minimal hepatic encephalopathy in asymptomatic HCV patients before and after antiviral treatment. Preliminary results from the EMERALD study**

Sharon Levy, Nir Bar, Oren Shibolet, **Helena Katchman**  
Liver unit, Department of Gastroenterology and Liver Diseases, Tel-Aviv Sourasky medical center and the Sackler faculty of medicine, Israel

09:00-09:20

**Hot topic 2: Withdrawal NUCs in HBeAg-negative patients**

**Dr. Ashley Brown**

Consultant Hepatologist, Imperial College Healthcare NHS Trust  
St. Mary's Hospital, UK



09:20-09:28

### **Hepatitis delta seroprevalence and molecular characterization of hepatitis B and delta confection in Israel**

Rachel Shirazi<sup>1</sup>, Daniela Ram<sup>1</sup>, Aviya Rakovsky<sup>1</sup>, Efrat Bucris<sup>1</sup>, Yael Gozlab<sup>1</sup>, Pninit Shaked-Mishan<sup>2</sup>, Orit Picard<sup>3</sup>, Yonat Shemer-Avni<sup>5</sup>, Haim Ben-Zvi<sup>6</sup>, Ora Halutz<sup>8</sup>, Ella Mendelson<sup>1</sup>, Rifaat Safadi<sup>9</sup>, Yoav Lurie<sup>7</sup>, Ziv Ben-Ari<sup>4</sup>, **Orna Mor<sup>1</sup>**

<sup>1</sup> Central Virology Laboratory, Ministry of Health, Israel

<sup>2</sup> Microbiology Laboratory, Carmel Medical Center, Israel

<sup>3</sup> Gastroenterology Laboratory, Sheba Medical Center, Israel

<sup>4</sup> Liver Disease Center, Sheba Medical Center, Israel

<sup>5</sup> Microbiology Laboratory, Soroka Medical Center, Israel

<sup>6</sup> Microbiology Laboratory, Rabin Medical Center, Israel

<sup>7</sup> Liver Unit, Shaare Zedek Medical Center, Israel

<sup>8</sup> Microbiology Laboratory, Sourasky Medical Center, Israel

<sup>9</sup> Liver Unit, Hadassah Medical Center, Israel

09:30-09:55

### **Coffee Break, Visit to the poster exhibit & Exhibit Hall**

10:05-11:31

### **SESSION 5: Hepatocellular carcinoma**

**"Blue" Hall**

**Chairs: Dr. Yaakov Maor, Dr. Yoram Menachem**

**Sponsored by**  **GILEAD**

10:05-10:13

### **Occurrence and Recurrence of Malignancies Post DAA Treatment in 5.1% of Patients- Single Center Experience**


**Assaf Issachar**, Orly Sneh-Arbib, Marius Braun, Amir Shlomai, Evelin Oxtrud, Chen Karuani, Hagar Banai, Yael Harif, Ran Tur-Kaspa, Michal Cohen-Naftali  
Liver Institute, Rabin Medical Center-Beilinson Hospital, Israel

10:15-10:35

### **Hot topic 3 - Occurrence and recurrence of HCC with DAAs treatment for HCV**

**Prof. Steven Flamm**

Division of Hepatology ,Northwestern University Feinberg School of Medicine ,Chicago, Illinois, USA



10:35-10:43

### **Cutting the Israeli Hepatitis C related “Hepatocellular Carcinoma” in 2016**

**Izhar Levy**<sup>1</sup>, Vered ben-Hakoon<sup>2</sup>, Rawi Hazzan<sup>3</sup>, Tova Neshet<sup>1</sup>, Igbaria Saleh<sup>3</sup>, Alexander Shtarkman<sup>3</sup>, Ravit Geva<sup>5</sup>, Tarek Saadi<sup>2</sup>, Ella Veitsman<sup>2</sup>, Oren Shibolet<sup>4</sup>, Rifaat Safadi<sup>1</sup>, Yoram Menachem<sup>4</sup>

<sup>1</sup> Liver unit, Hadassah Hospital, Israel, <sup>2</sup> Liver unit, Rambam Hospital, Israel, <sup>3</sup> Liver unit, HaEmek Hospital, Israel, <sup>4</sup> Liver unit, Ichilov Hospital, Israel, <sup>5</sup> Oncology, Ichilov Hospital, Israel

10:43-10:51

### **Hepatitis C virus infection is associated with increased rate of malignancy other than B-cell lymphoma and HCC**

**Eli Zuckerman**<sup>1</sup>, Hedy<sup>5</sup>. Rennert<sup>2</sup>, Gad Rennert<sup>2</sup>


<sup>1</sup> Liver Unit, Carmel Medical Center, Israel, <sup>2</sup> Department of Community Medicine and Epidemiology, Carmel Medical Center, Technion Faculty of Medicine, Israel

10:51-10:59

### **High-resolution liver cancer genomic profiling links etiology, epigenetic and mutation signatures**

**Meital Gal-Tanamy**<sup>1</sup>, Shira Perez<sup>1,2</sup>, Anat Lavi-Itzkovitz<sup>1,3</sup>, Antony Kaspi<sup>4</sup>, Ateret Davidovich<sup>1</sup>, Ana Tobar<sup>5</sup>, Alejandro Livoff<sup>6</sup>, Assy Nimer<sup>7</sup>, Evgeny Solomonov<sup>8</sup>, Assam El-Osta<sup>4</sup>, Gur Yaari<sup>3</sup>, Salomon M Stemmer<sup>9</sup>, Izhak Haviv<sup>2</sup>

<sup>1</sup> Molecular Virology Lab, Faculty of Medicine in the Galilee, Bar-Ilan University, Israel <sup>2</sup> Cancer Personalized Medicine and Diagnostic Genomics Lab, Faculty of Medicine in the Galilee, Bar-Ilan University, Israel <sup>3</sup> Bioengineering, Faculty of Engineering, Bar-Ilan University, Israel <sup>4</sup> Epigenetics in Human Health and Disease Laboratory, Department of Diabetes, Central Clinical School, Monash University, Australia <sup>5</sup> Institute of Pathology, Rabin Medical Center, Beilinson Campus, Israel <sup>6</sup> Department of Pathology, Barzilai Medical Center, Israel <sup>7</sup> Internal Medicine Department A, Western Galilee Medical Center, Israel <sup>8</sup> Department of Surgery, Ziv Medical Center, Israel <sup>9</sup> Davidoff Center, Rabin Medical Center, Beilinson Campus, Israel



10:59-11:07

**Fecal microbiota profiles as diagnostic biomarkers in cirrhosis and hepatocellular carcinoma and the impact of life style and nutrition**

Lena Lapidot<sup>1,2,3</sup>, Rita Nosenko<sup>4</sup>, Bella Gayshis<sup>2</sup>, Maria Likhter<sup>2</sup>, Wadia Hazou<sup>2</sup>, Dana Ben-Ami<sup>2</sup>, Tatiana Bradichevsky<sup>2</sup>, Ofir Harnoy<sup>2</sup>, Tal Engel<sup>2</sup>, Itai Kalisky<sup>2</sup>, Peretz Weiss<sup>2</sup>, Ella Veitsman<sup>2</sup>, Oranit Cohen-Ezra<sup>2</sup>, Yana Davidov<sup>2</sup>, Omry Koren<sup>4</sup>, **Michal Safran**<sup>1,2</sup>, Ziv Ben-Ari<sup>2,3</sup>

<sup>1</sup> Liver research laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel <sup>2</sup> Liver Diseases Center, Chaim Sheba Medical Center, Tel-Hashomer, Israel <sup>3</sup> The Sackler School of Medicine, Tel-Aviv University, Israel <sup>4</sup> Faculty of Medicine, Bar-Ilan University, Israel

11:07-11:15

**The potential of curcumin in combination with direct acting antivirals to treat Hepatitis C virus infection and prevent viral induced oncogenesis**

**Oshri Yosefov Levi**<sup>1</sup>, Ateret Davidovich<sup>1</sup>, Shimon Steingart<sup>2</sup>, Yoav Lurie<sup>2</sup>, Meital Gal Tanamy<sup>1</sup>


<sup>1</sup> Molecular Virology, Bar Ilan University faculty of medicine in the galilee, Israel <sup>2</sup> Digestive Disease Institute, Sha'are Zedek Medical Center, Israel

11:15-11:23

**Role of *Lens culinaris* Agglutinin-Reactive Fraction of  $\alpha$ -Fetoprotein (AFP-L3) and Des-Gamma-Carboxy Prothrombin ((DCP), Alone or in Combination, as Biomarkers for Hepatocellular Carcinoma surveillance**

**Ziv Ben-Ari**<sup>1,3</sup>, Gal Ben-Haim<sup>1</sup>, Ella Weitzman<sup>1</sup>, Oranit Cohen-Ezra<sup>1,3</sup>, Peretz Wiess<sup>1</sup>, Tania Berdichevsky<sup>1</sup>, Itai Kalisky<sup>1</sup>, Dana Silverberg<sup>1</sup>, Shani Dor-Hai<sup>1</sup>, Avishag Hassid<sup>1</sup>, Keren Tzaref<sup>1</sup>, Orly Azoulay<sup>2</sup>, Eyal Ashkenazi<sup>2</sup>, Yulia Kovalev<sup>2</sup>, Eli Zuckerman<sup>2,4</sup>

<sup>1</sup> Liver Diseases Center, Sheba medical Center, Israel <sup>2</sup> Liver Unit, Carmel Medical Center, Israel <sup>3</sup> Sackler School of Medicine, Tel Aviv University, Israel <sup>4</sup> Rappaport Faculty of Medicine, Technion, Israel



11:23-11:31

**Distinct antibody-mediated immune response against HCV correlates with spontaneous viral clearance**

**Anastasia Brodov**<sup>1</sup>, Yoav Bahat<sup>1</sup>, Ateret Davidovich<sup>1</sup>, Sivan Eliyahu<sup>1</sup>, Shiri Elmedvi<sup>1</sup>, Yael Weiss<sup>2</sup>, Jonathan Gershoni<sup>2</sup>, Marius Braun<sup>3</sup>, Assy Nimer<sup>4</sup>, Meital Gal-Tanamy<sup>1</sup>

<sup>1</sup> Molecular Virology Lab, Faculty of Medicine in the Galilee, Bar-Ilan University, Israel <sup>2</sup> Virology and Immunology Lab, Faculty of Biology, Tel Aviv University, Israel <sup>3</sup> Liver Institute, Rabin Medical Center, Sackler School of Medicine, Tel-Aviv University, Israel

<sup>4</sup> Liver Institute, Western Galilee Hospital, Nahariya, Israel

11:35-11:50

**Coffee Break, Visit to the poster Exhibit & Exhibit Hall**

11:50-13:00

**SESSION 6: Viral Hepatitis**

**"Blue" Hall**

**Chairs: Dr. Ohad Ezion, Dr. Matthias Carlebach**

Sponsored by  **GILEAD**

11:50-12:10

**Hot Topic 4 - Reactivation of HBV during treatment for HCV with DAAs**

**Prof. Daniel Shouval**

Liver Unit, Hadassah- Hebrew University Hospital, Ein- Kerem

12:10-12:18

**The Real-World Israeli experience of treating chronic hepatitis C , genotype 1 and 4 patients with advanced fibrosis with grazoprevir plus elbasvir: a large multi-center cohort**

**Eli Zuckerman**<sup>1</sup>, Eyal Ashkenazi<sup>1</sup>, Yulia Kovalev<sup>1</sup>, Oranit Cohen Ezra<sup>1,2</sup>, Ella Weitzman<sup>3</sup>, Tarek Saadi<sup>3</sup>, Matthias Carlebach<sup>4</sup>, Rawi Hazzan<sup>5</sup>, Rifaat Safadi<sup>6</sup>, Tova Goldberg<sup>6</sup>, Ran Oren<sup>6</sup>, Yafa Ashur<sup>7</sup>, Michal Carmiel<sup>8</sup>, Yona Kitayi<sup>9</sup>, Ruth Hadari<sup>9</sup>, Seif Abu-Mouch<sup>10</sup>, Rafael Bruk Bruk<sup>11</sup>, Yoram Menachem<sup>11</sup>, Helena Kathcman<sup>11</sup>, Oren Shibolet<sup>11</sup>, Orly Sneh<sup>12</sup>, Haim Shirin<sup>13</sup>, Ran Tur-Kaspa<sup>14</sup>, Marius Broun<sup>14</sup>, Michal Cohen Naftaly<sup>14</sup>, Amir Shlomai<sup>14</sup>

<sup>1</sup> Liver Unit, Carmel Medical Center, Technion Faculty of Medicine, Israel <sup>2</sup> Center of Liver Diseases, Sheba Medical Center, Israel <sup>3</sup> Liver Unit, Rambam Medical Center, Israel <sup>4</sup> Liver Unit, Bnai Zion Medical Center, Israel <sup>5</sup> Liver Clinic, Ha'emek





Medical Center, Israel <sup>6</sup>Liver Unit, Hadassah Medical Center, Israel <sup>7</sup>Liver Clinic, Southern District, CHS, Israel <sup>8</sup>Liver Clinic, Western Galilee Medical Center, Israel <sup>9</sup>Liver Clinic, Meir Medical Center, Israel <sup>10</sup>Liver Unit, Hillel Yaffe Medical Center, Israel <sup>11</sup>Liver Unit, Tel Aviv Medical Center, Israel <sup>12</sup>Liver Clinic, Talpiot Clinic, CHS, Israel <sup>13</sup>Department of Gastroenterology, Assaf Harofeh Medical Center, Israel <sup>14</sup>Liver Institute, Rabin Medical Center, Israel

12:18-12:26

### **Vertical HBV transmission in North West Galilee**

Jamalat Jaas<sup>1</sup>, **Rifaat Safadi**<sup>2</sup>, Shihab Shihab<sup>1</sup>

<sup>1</sup> Acre Health Bureau, Israeli Ministry of Health, Akco District, Israel

<sup>2</sup> Liver and Gastroenterology Units, Hadassah-Hebrew University Hospital, Israel

12:26-12:34

### **Hepatitis B virus infection after the implementation of the vaccine program in Israel**

**Eli Zuckerman**<sup>1</sup>, Hedy S. Rennert<sup>2</sup>, Gad Rennert<sup>2</sup>

<sup>1</sup> Liver Unit, Carmel Medical Center, Technion Faculty of

Medicine, Israel <sup>2</sup>Community Medicine and department of Epidemiology, Carmel Medical Center, Israel

12:34-12:42

### **Hepatitis E Virus in Israeli HIV Infected Patients**


**Rasha Daniel**<sup>1,2,4</sup>, Shira Zelber-Sagi<sup>2</sup>, Margalit Lorber<sup>3</sup>, Mira Barak<sup>4</sup>, Orly Azulay<sup>1</sup>, Eli Zuckerman<sup>1</sup>

<sup>1</sup> Liver Unit, Carmel Medical Center, Israel <sup>2</sup>Faculty of Public

Health, Haifa University, Israel <sup>3</sup>Autoimmune, HIV/AIDS

Disease Unit, RAMBAM Medical Center, Israel <sup>4</sup>Nesher Central Laboratories, Haifa and Western Galilee District, CHS, Israel





12:42-12:50

**Automated Low Flow Pump System (AIFAPUMPÓ) For the Treatment of Refractory Ascites- Initial Israeli Experience**

**Michal Cohen**<sup>1,3</sup>, Asaf Issachar<sup>1,3,4</sup>, David Arnovitz<sup>2,3</sup>, Orly Sneh-Arviv<sup>1,3</sup>, Amir Shlomai<sup>1,3,4</sup>, Ran Tur Kaspá<sup>1,5</sup>, Marius Braun<sup>1,3</sup>

<sup>1</sup> Liver Unit, Beilinson Hospital, Israel <sup>2</sup> General Surgery Department, Beilinson Hospital, Israel <sup>3</sup> Sackler Faculty of Medicine, Tel Aviv University, Israel <sup>4</sup> Internal Medicine Department D, Beilinson Hospital, Israel <sup>5</sup> Faculty of Medicine, Bar Ilan University, Israel

12:50-13:00

**Mr. Húlio Burman** - Hetz

13:00-13:30

**Business Meeting**

13:30-14:30

**Lunch - Hotel's Restaurant**



## INVITED SPEAKERS



**Dr. Ashley Brown** is a Consultant Hepatologist at St Mary's Hospital, Paddington and Adjunct Reader in Medicine at Imperial College London. He has a major clinical and research interest in viral hepatitis, has been investigator on more than 40 clinical trials of novel hepatitis therapies and has published nearly 50 papers in peer-reviewed journals. He is currently heavily engaged in developing policy for ensuring access and pathways into care for difficult-to-reach populations, including prisoners and PWID, and looking at the health economics of screening for and treating HCV.

He is former Chair of the London Joint Working Group on HCV in PWID and of the British Viral Hepatitis Group; he sits on the HepC Coalition; and has recently been co-opted onto the European Liver Patients' Association Task Force



**Professor Stephan Urban** is head of the Translational Virology unit at the Department of Infectious Diseases, Molecular Virology at Heidelberg University Hospital. He is also Professor at the Faculty for Biosciences at the University of Heidelberg and Project Coordinator in the DZIF TTU Hepatitis. He completed a Diploma in Biochemistry at the University of Tübingen in 1991 and was awarded a Ph.D. in 1995 under Prof. Dr. P.H. Max-Planck-Institut für Biochemie, Martinsried and undertook

Postdoctoral research at the Centre for Molecular Biology (ZMBH), Heidelberg University with Prof. Dr. H. Schaller.


Between 2008 and 2012 he was Project coordinator of the BMBF-network «Innovative Therapies» and from 2011 Project coordinator in the DZIF TTU hepatitis. In 2014 he was awarded with the 1. DZIF Research Award.

Professor Urban's research interests include Molecular mechanisms of Hepatitis B- and Hepatitis D Virus/host interactions with a focus on the early and late events of viral infection; Identification of hepadnaviral receptors and structural analyses of virus receptor interactions; Development of novel cell culture systems and animal models for HBV and HDV; Clinical development of entry inhibitors for HBV and HDV infection; Development of hepatotropic drugs for the therapy of liver diseases. Between 2008 and 2014 Professor Urban has published in numerous peer reviewed journals on Hepatitis B, C and D. He is the recipient of the Pettenkofer Price of the Pettenkofer Foundation, Fellowship of the Heinz Schaller and Chica Foundations and Study Foundation of the German People Awards.



**Steven L. Flamm, MD** is a Professor of Medicine and Surgery with the Division of Hepatology at Northwestern University Feinberg School of Medicine in Chicago, Illinois. He serves as the Chief of Transplantation Hepatology and Medical Director of Liver Transplantation.

Dr. Flamm received his MD degree from the University of Pennsylvania School of Medicine. He completed both a clinical fellowship in gastroenterology and a



research fellowship in gastroenterology and hepatology at Beth Israel Hospital, Harvard Medical School. He then received further specialized training, completing a clinical fellowship in hepatology and liver transplantation at The Deaconess Hospital, Harvard Medical School.

Dr. Flamm is a member of the American Gastroenterological Association (AGA), American Association for the Study of Liver Diseases (AASLD), and is a fellow in the American College of Gastroenterology (ACG). He has served as the Region 7 Representative to the UNOS Liver and Intestine Committee and on the Publication and Practice Guidelines Committees of the AASLD. Currently, he is a trustee of the AASLD Foundation and chairs the AASLD Development Committee. Dr. Flamm is also a member of the Clinical Practice Guidelines Committee of the AGA and the Illinois Hepatitis C State Task Force. Dr. Flamm was also the 2015 American Liver Foundation Illinois Chapter Honoree.

Dr. Flamm has published widely in the field of hepatic diseases and has spoken both nationally and internationally on many other liver-related topics including viral hepatitis, autoimmune hepatitis, hepatic encephalopathy, and liver transplantation. He has an active clinical research program for patients with many different chronic liver diseases including chronic viral hepatitis (HBV and HCV) hepatic encephalopathy, acute liver failure and non-alcoholic fatty liver disease (NAFLD).



**Gideon Hirschfield** graduated from Trinity College Oxford in 1994 (having been awarded the University of Oxford Wronker Prize for most outstanding performance in the Final Honour School), and subsequently from Cambridge where he completed his clinical studies with distinction. He undertook junior medical posts at the Hammersmith and Royal Brompton hospitals before moving to a MRC Clinical Research Fellowship at UCL. There he worked within the uniquely

translational National Amyloidosis Centre/Centre for Acute Phase Proteins, with Sir Mark Pepys FRS as his supervisor. His PhD was focussed on the development of inhibitors of C-reactive protein. He completed his advanced Gastroenterology and Hepatology training in Cambridge, and was awarded Specialist status in 2007. Until January 2012 he worked in Toronto, Canada, where he was a Staff Physician and Assistant Professor of Medicine at the University Health Network and University of Toronto. During this time he managed one of the largest autoimmune liver disease cohorts in North America, and with his colleague Prof Kathy Siminovitch published the seminal genetic observations underpinning the IL-12 signalling axis as critical to the pathophysiology of PBC. He now divides his time between translational research in autoimmune liver disease, and his clinical, Transplant/Hepatology, practice at the QE hospital. In particular the cohorts of patients with PBC, PSC and AIH he manages are some of the largest internationally, providing Gideon unique clinical skills in their management and recruitment to clinical trials of novel therapies.

Sponsors

Platinum



Gold



Silver



Bronze

